Bionano Q2 Revenue Jumps 21% to $8.2M, Guides FY26 Revenue to $31-33M
BNGO sits 17% above its 52-week low of $1.
Summary
Bionano delivered Q2 revenue of $8.2M, up 21% YoY, driven by a 31% jump in consumables sales and 27% more flow cells sold, with increased clinical adoption noted. Gross margin ticked up to 53%, while adjusted operating expenses fell 2%. The company guided Q3 revenue to $8.2-$8.6M and full-year 2026 to $31-$33M, implying accelerating growth. This follows a Q1 marked by a going concern warning and a net loss of $8.3M; the Q2 print shows improving top-line momentum and cost discipline. The full retirement of secured convertible debentures during the quarter removes a key overhang. With the recent return of CSO Alex Hastie and mounting clinical evidence for OGM, the revenue trajectory is strengthening, though the company remains small-cap and cash-constrained.
At the time of this announcement, BNGO was trading at $1.17 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.3M. The 52-week trading range was $1.00 to $5.50. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.